Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | ECE1 | P42892 | 12/20 | 0.60 |
| ▸ | GHSR | Q92847 | 1/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488096 | 0.96 | ACE (0.60) | ACEECE1GHSRERAP2 | |
| SCHEMBL31344343 | 0.96 | GHSR (0.65) | ACEECE1GHSR | |
| SCHEMBL29499092 | 0.96 | ACE (0.68) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL31696723 | 0.94 | ACE (0.60) | ACEECE1GHSRERAP2 | |
| SCHEMBL30051087 | 0.92 | ACE (0.75) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL10865665 | 0.92 | ERAP2 (0.64) | ACEECE1GHSRERAP2 | |
| SCHEMBL30834729 | 0.91 | ACE (0.61) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL1228369 | 0.90 | ACE (0.78) | ACEECE1ALOX15 | |
| SCHEMBL9235801 | 0.90 | ACE (0.78) | ACEECE1ALOX15 | |
| SCHEMBL9235805 | 0.90 | ACE (0.78) | ACEECE1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | ACE 3899/4885ECE1 1368/4885GHSR 3695/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | ACE 3899/4885ECE1 1368/4885GHSR 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.